The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.

Slides:



Advertisements
Similar presentations
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Advertisements

Integrated Substance Abuse Programs Bridges have been built: Is anyone using them? Richard A. Rawson, Ph.D, Professor Supported by: National Institute.
Ambulatory Withdrawal Management Greg Sutmiller MS, LPC, LADC.
Effective Risk Management Strategies in Outpatient Methadone Treatment: Clinical Guidelines and Liability Prevention Curriculum Module 9 Special Populations.
Aftercare Attendance Partially Moderated by History of Physical Abuse and Gender Louise F. Haynes 1 ; Amy E. Herrin 1 ; Rickey E. Carter 1 ; Sudie E. Back.
 William Frank Barker, LPC, MAC Diane Diver, LMSW, CAC II.
DALLAS COALITION FOR TREATMENT IMPROVEMENT A sudden rise in Heroin use among adolescents and young adults served as a call to action and inspired this.
Swinomish Wellness Program
Translating Research to Practice in Treating Substance Use Disorders Richard Rawson, Ph. D. UCLA Drug Abuse Research Center Matrix Institute on Addictions.
Comparative Effectiveness Research in the National Drug Abuse Treatment Clinical Trials Network (CTN) CDR Steven Sparenborg, Ph.D., Udi Ghitza, Ph.D.,
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox Protocol Stopping addiction in 8 hours without withdrawal and without relapse.
Slide 1 of 20 Overview of National Treatment Outcome Studies Charts Prepared & Released for Public Use by Dwayne Simpson (TCU), Robert Hubbard (NDRI-NC),
Buprenorphine : A New Approach for Opioid Treatment Thomas E. Freese, Ph.D. Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
HIV and Behavioral Health: An Update from SAMHSA Elinore F. McCance-Katz, MD, PhD Chief Medical Officer Substance Abuse and Mental Health Services Administration.
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) For Infusion Into Undergraduate Generalist’s Courses A Generalist’s Course Developed by the Mountain.
F/C AETC Faculty HIV HCV Thursday, March 12, 2015 | 1:30pm EDT Medical Facilitator/Didactic Presenter Todd S. Wills, MD University of South Florida Case.
Addiction Treatment Works! Through Collaboration and Problem Solving amongst all disciplines.
HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.
Bureau of Drug and Alcohol Services (BDAS) /DHHS Presentation to the Gaming Study Commission March 16 th, 2010 Joe Harding – Director –
Suboxone as an Adjunctive Medication, Not Maintenance Dennis M. Donovan, Ph.D. UW Alcohol & Drug Abuse Institute Patricia C. Knox, Ph.D. Recovery Centers.
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
NIDA/SAMHSA Blending Initiative Overview. Advances in science are giving us a broad range of promising options for treating substance use disorders, BUT.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
American Association for the Treatment of Opioid Dependence, Inc National Conference, Atlanta April 25, 2006 Evaluation of the Impact of Opioid Treatment.
FUTURE HIV RESEARCH EFFORTS PLANNED FOR THE CLINICAL TRIALS NETWORK James L. Sorensen, Ph.D. Susan Tross, Ph.D. Raul Mandler, M.D. University of California,
Implementation Science and the Adoption of Practice in Addiction Treatment Harold I Perl, PhD Center for the Clinical Trials Network National Institute.
Chapter 3 Addictions: Theory and Treatment. Drug Addiction Behavioral pattern of drug use Overwhelming involvement Securing of its supply Tendency to.
Opioid addiction treatment: Challenges (and opportunities) for community practice Marc Fishman MD.
Making the Best Use of Performance Data Connie Weisner, DrPH, MSW University of California at San Francisco and Division of Research, Northern California.
Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006
For Pain or Not for Pain: Methadone Madness
A Strategy for Inpatient Integration Terry Horton, MD, FACP Delaware Valley Node September 21, 2010.
Adopting Buprenorphine: Barriers & Incentives Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley Node American Psychological Association,
Exploration of the Substance Abuse Treatment Workforce: Education, Preparation and Certification Traci Rieckmann, Ph.D., Bret Fuller, Ph.D, Dennis McCarty,
Patient and Staff Satisfaction in Outpatient Substance Abuse Treatment Programs A. Kulaga 1, B. McClure 1, J. Rotrosen 1, P. Crits-Christoph 2, S. Ring-Kurtz.
Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment.
Coverage and Management of Medications for Treating Substance Abuse in Health Plans Constance M. Horgan, Sc.D. Sharon Reif, Ph.D. Dominic Hodgkin, Ph.D.
The Counseling Center, Inc. Devoted to the prevention and treatment of alcoholism and other drug addictions. We promote opportunities for individuals and.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.
BUPRENORPHINE TREATMENT: A Training For Addiction Professionals BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Clinical Trial Finds That While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use Among Those Dependent on Prescription Opioids, 91% Were Not.
1 Prescribing Pain Medication – Guidelines for the Emergency Department April 22, 2012 Jennifer Sabel, PhD.
Buprenorphine {Suboxone®, Subutex®}
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Buprenorphine Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center.
1 Use of Pharmacotherapies by Substance Abuse Treatment Facilities November 2007 Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration.
Benjamin J. Pariser, DO RASE Physician.  This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery.
Adoption of Motivational Interviewing/Motivational Enhancement Therapy Joseph Guydish PhD, Sarah Turcotte Manser MA, Martha A. Jessup RN PhD, Barbara Tajima.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Rev In the Diffusion of Innovations Everyone Changes: Linking Practice with Scientific Research James L. Sorensen, Ph.D. University of California,
Gregory S. Brigham, Ph.D., CEO
Addressing the Intersection of Substance Abuse and Viral Hepatitis
Medication-Assisted Therapy at Coleman Profession Services
Medication-Assisted Treatment 101: Breaking the Stigma
Maintenance Treatment
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Strategic Initiatives to Address Opioid Overdose & Addiction
Medically assisted treatment
Presentation transcript:

The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley Node American Psychological Association, San Francisco, CA (August 2007) Support from The Ohio Valley Node of the NIDA CTN, NIDA 5 U10 DA

Topics  A medication example of moving from clinical trial to clinical practice: Buprenorphine short-term taper at Maryhaven  Importance of ongoing monitoring, evaluation and, feedback on provider modifications to interventions

Partial vs. Full Opioid Agonist Dose of Opiate Opiate Effect death Full Agonist (e.g., methadone) Partial Agonist (e.g. Naloxone) Antagonist (e.g. buprenorphine)

 Two, open-label, randomized clinical trials, residential & outpatient.  Compared Buprenorphine-Naloxone (n = 77) and Clonidine (n = 36) for 13 day opiate detoxification in residential.  Initiated in 6 Community Treatment Programs.  Outcome: BUP/NX = 77% (59) Present and Clean on day 13 Clonidine = 22% (8) Present and Clean on day 13 NIDA CTN Buprenorphine- Naloxone Detoxification Protocols Ling, W., Amass, L., Shoptaw, S., Annon, J. J., Hillhouse, M., Babcock, D., Brigham, G., Harrer, J., Reid, M., Muir, J., Buchan, B., Orr, D., Woody, G., Krejci, J., Ziedonis, D., & Buprenorphine Study Protocol Group (2005). A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction, 100,

Adopt This Treatment? “We must find a better way to treat these patients, more that half of them are not continuing with treatment” Maryhaven Medical Director

Three Groups  Prior to BNX implementation, n = 157 Admitted prior to BNX Implementation between 6/10/03 - 8/24/03  After BNX implementation but no BNX, n = 227 Admitted between 8/25/03 - 1/31/04, but did not take BNX  Received BNX, n = 64 Admitted between 8/25/03 - 1/31/04 and received BNX

BUP/NX Taper at Maryhaven

Patient Demographics FemaleMaleAfrican American White Prior to BNX No BNX BNX % of Patients

Treatment Completion & Engagement Prior To BNX No BNX BNX TX Completed Detoxification Program Continued Early TX Engagement % of Patients * p =.0001 AB * *  Brigham, G. S., Amass, L., Winhusen, T., Harrer, J. M., & Pelt, A. (2007). Using buprenorphine short-term taper to facilitate early treatment engagement. Journal of Substance Abuse Treatment, 32,

QI Report Detects Problem  Maryhaven QI data showed decline in completion rates as the number of admissions increased.  Further investigation indicated that initial indicator of completion drop-off was not accurate but transfer drop off was substantial.  Chart review revealed adaptation of the treatment to treat greater number of patients with the unintended result of lower success rates.

Two Groups  100 patients admitted for short-term Buprenorphine Taper between 6/01/04 & 12/31/04 BNX 7 Day Taper, n = 29 BNX 13 Day Taper, n = 71

BUP Taper Admits June Thru December 2004 AGE 7 Day13 Day Range Mean3635 Median3033

Taper Completion & Engagement

Clinical Significance of Transfer  Detoxification is not a treatment for addiction  (National Institute on Drug Abuse (1999). Principles of drug addiction treatment: A research-based guide. NIH Publication No  A critical quality indicator for detoxification is engagement in ongoing treatment  Washington Circle Group (McCorry, F., Garnick, D.W., Bartlett, J., Cotter, F., & Chalk, M. (2000). Developing performance measures for alcohol and other drug services in managed care plans. Joint Commission on Quality Improvement, 26 (11), ; Garnick, D.W., Lee, M.T., Chalk, M., Gastfriend, D., Horgan, C.M., McCorry, F., McLellan, A.T., & Merrick, E.L. (2002). Establishing the feasibility of performance measures for alcohol and other drugs. Journal of Substance Abuse Treatment, 23, )  Center for Substance Abuse Treatment (CSAT). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.

Risks of Opiate Detoxification  BNX detoxification taper without ongoing treatment leads to rapid relapse  Fiellin, D.A., Kleber, H., Trumble-Hejduk, J.G., McLellan, A.T., & Kosten, T.R. (2004). Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment, 27,  Return to opioid use after even a brief period of abstinence may increase the risk for accidental drug overdose  Strang, J., McCambridge, J., Best, D., Beswick, T. Bearn, J., Rees, S., & Gossop, M. (2003). Loss of tolerance and overdose mortality after inpatient opiate detoxification. British Medical Journal. May 2003;

Timeline of Opiate Treatment Innovations at Maryhaven  2001 BUP Clinical Trial  2003 Adoption of BUP Taper  2005 Adoption of BUP Maintenance  2007 Open OTP with both Methadone and BNX

Conclusion  Identify important outcomes  Measure & monitor outcomes  Evaluate impact of provider modifications to intervention; even small shifts in practice can have significant unintended consequences  Provide timely feedback to clinicians and other stake holders